Leuprolide
- Generic Name
- Leuprolide
- Brand Names
- Camcevi, Eligard, Fensolvi, Lupaneta Pack 1-month, Lupron, Lupron Depot-ped, Viadur, Zeulide Depot
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N16O12
- CAS Number
- 53714-56-0
- Unique Ingredient Identifier
- EFY6W0M8TG
- Background
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the...
- Indication
Leuprolide is indicated for the treatment of advanced prostate cancer and as palliative treatment of advanced prostate cancer.
It is also used for the treatment of pediatric patients with central precocious puberty (CPP).
...
- Associated Conditions
- Advanced Prostate Cancer, Anemia, Central Precocious Puberty (CPP), Endometriosis
- Associated Therapies
- Palliative Treatment
Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Target Recruit Count
- 77
- Registration Number
- NCT04249154
- Locations
- 🇨🇦
McGill University Health Centre- Cedars Cancer Centre, Montreal, Quebec, Canada
🇨🇦McGill University Health Centre-Cedars Cancer Centre, Montréal, Quebec, Canada
Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- Wonju Severance Christian Hospital
- Target Recruit Count
- 164
- Registration Number
- NCT04248621
- Locations
- 🇰🇷
Department of Urology, Chonnam National University, School of Medicine, Gwangju, Korea, Republic of
🇰🇷Department of Urology, Kyungpook National University, School of Medicine, Daegu, Korea, Republic of
🇰🇷Department of Urology, Eulji University, College of Medicine, Daejeon, Korea, Republic of
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-11
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT04194554
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Cornell University, New York, New York, United States
Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis
- First Posted Date
- 2019-04-30
- Last Posted Date
- 2020-12-11
- Lead Sponsor
- ASKA Pharmaceutical Co., Ltd.
- Target Recruit Count
- 335
- Registration Number
- NCT03931915
- Locations
- 🇯🇵
Rinkan Clinic, Kanagawa, Japan
🇯🇵Shinsuma Hospital, Hyogo, Japan
🇯🇵Tsujinaka Hospital Kashiwanoha, Chiba, Japan
PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate
- Conditions
- Interventions
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 122
- Registration Number
- NCT03900637
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Taipei Veterans General Hospital, Taiwan
- Target Recruit Count
- 5000
- Registration Number
- NCT03778359
- Locations
- 🇨🇳
Peng-Hui Wang, Taipei county, Taipei, Taiwan
Comparison of a Novel Leuprolide With Market Leuprolide
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Lee's Pharmaceutical Limited
- Target Recruit Count
- 48
- Registration Number
- NCT03662958
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
- Conditions
- Interventions
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 14
- Registration Number
- NCT03572387
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 300
- Registration Number
- NCT03555578
- Locations
- 🇯🇵
Takeda Selected Site, Tokyo, Japan
Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- National Cancer Center, Korea
- Target Recruit Count
- 114
- Registration Number
- NCT03497702
- Locations
- 🇰🇷
National Cancer Center, Goyang-si, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.